Analysts expect that Amedisys Inc (NASDAQ:AMED) will report $394.96 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $390.40 million and the highest is $400.46 million. Amedisys reported sales of $366.30 million in the same quarter last year, which indicates a positive year over year growth rate of 7.8%. The business is scheduled to announce its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Amedisys will report full-year sales of $394.96 million for the current fiscal year. For the next financial year, analysts forecast that the firm will post sales of $1.63 billion per share, with estimates ranging from $1.60 billion to $1.66 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Amedisys.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. During the same quarter in the previous year, the business posted $0.36 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year.

A number of research analysts have recently issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a research report on Tuesday, November 21st. SunTrust Banks reissued a “buy” rating and set a $70.00 target price on shares of Amedisys in a research report on Friday, November 10th. Robert W. Baird boosted their target price on shares of Amedisys from $50.00 to $60.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Craig Hallum reissued a “buy” rating and set a $68.00 target price (up previously from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $62.00 target price (up previously from $56.00) on shares of Amedisys in a research report on Thursday, November 9th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) opened at $54.16 on Tuesday. Amedisys has a twelve month low of $38.00 and a twelve month high of $65.91. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market cap of $1,794.23, a PE ratio of 25.30, a PEG ratio of 1.28 and a beta of 0.70.

Several institutional investors and hedge funds have recently bought and sold shares of AMED. Sterling Capital Management LLC raised its position in Amedisys by 15.8% during the third quarter. Sterling Capital Management LLC now owns 16,654 shares of the health services provider’s stock worth $932,000 after acquiring an additional 2,268 shares during the period. Piedmont Investment Advisors LLC raised its position in Amedisys by 286.9% during the third quarter. Piedmont Investment Advisors LLC now owns 23,422 shares of the health services provider’s stock worth $1,311,000 after acquiring an additional 17,368 shares during the period. California Public Employees Retirement System raised its position in Amedisys by 4.0% during the third quarter. California Public Employees Retirement System now owns 64,785 shares of the health services provider’s stock worth $3,625,000 after acquiring an additional 2,485 shares during the period. Point72 Asset Management L.P. raised its position in Amedisys by 337.0% during the third quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock worth $26,528,000 after acquiring an additional 674,044 shares during the period. Finally, OxFORD Asset Management LLP raised its position in Amedisys by 13.4% during the third quarter. OxFORD Asset Management LLP now owns 40,611 shares of the health services provider’s stock worth $2,267,000 after acquiring an additional 4,784 shares during the period. Hedge funds and other institutional investors own 94.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/analysts-expect-amedisys-inc-amed-will-post-quarterly-sales-of-394-96-million/1744298.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.